ad-prevention-vs-treatment

📖 Wiki Page

mechanism3390 wordssynced 2026-04-02

Alzheimer's Disease: Prevention vs Treatment — A Comparative Scorecard

Introduction

Ad Prevention Vs Treatment Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

This page provides a systematic comparison of therapeutic approaches for Alzheimer's disease (AD) based on their potential for prevention (preventing disease onset in at-risk individuals) versus treatment (slowing or reversing disease progression in those with established pathology). This framework recognizes a fundamental insight in [AD](/diseases/alzheimers-disease) research: approaches that fail in late-stage treatment trials may still hold promise for prevention, and vice versa [@ritchie2024]. [@livingston2024]

Overview

[AD](/diseases/alzheimers-disease) Prevention vs Treatment Scorecard provides a comprehensive framework for understanding therapeutic strategies and experimental approaches in Alzheimer's disease research. These resources synthesize current knowledge about prevention strategies, treatment modalities, and experimental models used in [AD](/diseases/alzheimers-disease) research. [@livingston2025]

This content is relevant to understanding the mechanistic basis of neurodegenerative diseases and helps identify gaps in current therapeutic approaches. [@sperling2024]

--- [@crousbou2025]

Core Framework

The key distinction between prevention and treatment approaches lies in the disease stage at which intervention occurs: [^6]

...

Alzheimer's Disease: Prevention vs Treatment — A Comparative Scorecard

Introduction

Overview

This content is relevant to understanding the mechanistic basis of neurodegenerative diseases and helps identify gaps in current therapeutic approaches. [@sperling2024]

--- [@crousbou2025]

Core Framework

The key distinction between prevention and treatment approaches lies in the disease stage at which intervention occurs: [^6]

Prevention: Target individuals with preclinical or prodromal [AD](/diseases/alzheimers-disease) (normal cognition or mild cognitive impairment, but biomarker evidence of amyloid/[tau](/proteins/tau-protein) pathology)
Treatment: Target individuals with mild, moderate, or severe [AD](/diseases/alzheimers-disease) dementia

This distinction has profound implications for trial design, endpoint selection, and expected treatment effects [@livingston2024]. [^7]

Prevention vs Treatment Scorecard

Legend: Blue bars = Prevention Potential | Orange bars = Treatment Potential [^8]

Therapeutic Approaches: Detailed Scoring

Anti-Amyloid Monoclonal Antibodies

| Approach | Prevention Score | Treatment Score | Key Evidence | [@ref]
|----------|-----------------|-----------------|--------------| [@henley2019]
| Lecanemab (Leqembi) | 8/10 | 4/10 | CLARITY-[AD](/diseases/alzheimers-disease) showed 27% slowing in early [AD](/diseases/alzheimers-disease); TRAILBLAZER-ALZ3 may show prevention benefit [@livingston2025] | [@karran2011]
| Donanemab (Kisunla) | 7/10 | 5/10 | TRAILBLAZER-AD2 showed 35% slowing; TRAILBLAZER-ALZ3 for prevention [@sperling2024] | [@ngandu2015]
| Aducanumab (Aduhelm) | 6/10 | 3/10 | Conflicting efficacy data; ENGAGE/EMERGE differed by population [@crousbou2025] | [@willis2006]
| Solanezumab | 9/10 | 2/10 | Failed in DIAN-TU for dominantly inherited [AD](/diseases/alzheimers-disease); A4 study in preclinical [AD](/diseases/alzheimers-disease) ongoing [^6] | [@williamson2019]

Key Insight: Anti-amyloid antibodies consistently perform better in earlier disease stages. The relationship between amyloid clearance and clinical benefit is stronger in prevention settings [^7]. [@fratiglioni2000]

BACE Inhibitors

| Approach | Prevention Score | Treatment Score | Key Evidence | [@nedergaard2020]
|----------|-----------------|-----------------|--------------| [@estruch2013]
| Verubecestat | 9/10 | 1/10 | Failed in prodromal [AD](/diseases/alzheimers-disease) (EPOCH) but theoretically sound for prevention [^8] | [@malm2023]
| Lanabecestat | 8/10 | 1/10 | Failed in LVRI/LAVEL; too late in disease course [@ref] | [@wischik2023]
| Atabecestat | 7/10 | 2/10 | Failed in EARLY trial due to liver toxicity; concept valid [@henley2019] | [@novak2017]

Key Insight: BACE inhibitors shut down amyloid production entirely, but clinical trials enrolled patients too late in disease progression. Prevention trials would require 10+ year treatment windows [@karran2011]. [@ulland2017]

Lifestyle and Modifiable Risk Factor Interventions

| Intervention | Prevention Score | Treatment Score | Evidence Strength | [@dejanovic2022]
|--------------|-----------------|-----------------|-------------------| [@spangenberg2019]
| Physical Exercise | 9/10 | 4/10 | Strong epidemiological data; FINGER trial shows benefit in at-risk populations [@ngandu2015] | [@nguon2024]
| Cognitive Training | 8/10 | 3/10 | ACTIVE trial showed long-term benefits [@willis2006] | [@craft2019]
| Cardiovascular Risk Management | 9/10 | 5/10 | SPRINT-MIND showed blood pressure control benefits [@williamson2019] | [@burns2021]
| Social Engagement | 8/10 | 3/10 | Observational data strong; interventional trials challenging [@fratiglioni2000] | [@bateman2021]
| Sleep Optimization | 8/10 | 4/10 | Glymphatic clearance of amyloid during sleep; intervention feasible [@nedergaard2020] | [@sperling2014]
| Diet (MIND/Mediterranean) | 8/10 | 4/10 | PREDIMED trial supports cardiovascular benefits; cognitive data emerging [@estruch2013] | [@ahead2024]

Anti-Tau Therapies

| Approach | Prevention Score | Treatment Score | Key Evidence | [@miller2023]
|----------|-----------------|-----------------|--------------| [@lopez2021]
| Anti-[tau](/proteins/tau-protein) antibodies (gosuranemab, tilavonemab) | 5/10 | 6/10 | Failed in treatment trials; prevention potential unclear [@malm2023] | [@livingston2024a]
| Tau aggregation inhibitors (LMTM) | 4/10 | 7/10 | Failed in phase 3; post-hoc analysis suggested benefit in earlier stages [@wischik2023] | [@deal2017]
| Active vaccination (AADvac1) | 5/10 | 5/10 | Phase 2 showed [tau](/proteins/tau-protein) reduction; prevention potential being explored [@novak2017] |

Microglial Modulation

| Approach | Prevention Score | Treatment Score | Key Evidence |
|----------|-----------------|-----------------|--------------|
| [TREM2](/proteins/trem2) agonists | 6/10 | 7/10 | Genetic evidence strong; therapeutic window may be broader [@ulland2017] |
| Anti-C1q (戈3) | 6/10 | 7/10 | Synaptic protection mechanism; both settings relevant [@dejanovic2022] |
| CSF1R inhibitors (pegunenalus) | 5/10 | 6/10 | Microglial depletion; safety concerns in both settings [@spangenberg2019] |

Metabolic and Vascular Approaches

| Approach | Prevention Score | Treatment Score | Key Evidence |
|----------|-----------------|-----------------|--------------|
| GLP-1 agonists | 7/10 | 8/10 | LIRAD trial showing cognitive benefits; broad mechanism [@nguon2024] |
| Intranasal insulin | 6/10 | 7/10 | SNIFF trials showed memory benefits in early [AD](/diseases/alzheimers-disease) [@craft2019] |
| Pioglitazone (PPAR-γ agonist) | 7/10 | 4/10 | TOMMORROW trial in preclinical [AD](/diseases/alzheimers-disease) [@burns2021] |

Prevention Trials: Current Landscape

Dominantly Inherited [AD](/diseases/alzheimers-disease) (DIAN)

| Trial | Intervention | Population | Status | Key Findings |
|-------|-------------|------------|--------|--------------|
| DIAN-TU | Solanezumab + Gantenerumab | Autosomal dominant [AD](/diseases/alzheimers-disease) mutation carriers | Completed | Gantenerumab reduced plaque; solanezumab showed trends; neither reached primary endpoint [@bateman2021] |
| DIAN-TU-001 | JNJ-63733657 (anti-[tau](/proteins/tau-protein) | DIAN mutation carriers | Active | Targeting [tau](/proteins/tau-protein) spread |
| DIAN-TU-002 | E2814 (anti-[tau](/proteins/tau-protein) | DIAN mutation carriers | Active | Tau antibody |

Preclinical/Sporadic [AD](/diseases/alzheimers-disease) Prevention

| Trial | Intervention | Population | Status | Key Findings |
|-------|-------------|------------|--------|--------------|
| A4 Study | Solanezumab | Preclinical [AD](/diseases/alzheimers-disease) (elevated amyloid) | Completed | Failed to slow cognitive decline; elevated amyloid alone may not be sufficient [@sperling2014] |
| AHEAD 3-45 | Lecanemab | Preclinical and prodromal [AD](/diseases/alzheimers-disease) | Active | Lower dose may show prevention benefit [@ahead2024] |
| TOMMORROW | Pioglitazone | Preclinical [AD](/diseases/alzheimers-disease) (biomarker risk) | Completed | Failed to demonstrate prevention; concept valid but compound suboptimal [@miller2023] |
| Generation Studies | CAD106 + CNP520 | Preclinical [AD](/diseases/alzheimers-disease) (APOE4 carriers) | Terminated | Safety concerns with BACE inhibitor component [@lopez2021] |

Lancet Commission 2024 Modifiable Risk Factors

The Lancet Commission on dementia prevention, intervention, and care identified 14 modifiable risk factors that account for approximately 40% of dementia cases worldwide [@livingston2024a]:

Risk Factor Intervention Scoring

| Risk Factor | Prevalence | Intervention Availability | Prevention Potential | Notes |
|-------------|------------|--------------------------|---------------------|-------|
| Hearing loss | 8% | High (hearing aids) | 9/10 | Strongest modifiable risk; hearing aid use reduces risk by 32% [@deal2017] |
| Less education | 7% | High (lifelong learning) | 8/10 | Cognitive reserve hypothesis |
| Hypertension | 5% | High (medications) | 8/10 | SPRINT-MIND showed 15% reduction in MCI/dementia [@williamson2019] |
| Smoking | 5% | Moderate (cessation programs) | 7/10 | Even late cessation shows benefit |
| Obesity | 3% | High (lifestyle/medication) | 7/10 | Mid-life obesity strongest risk |
| Physical inactivity | 3% | High (exercise programs) | 9/10 | Most actionable modifiable factor |
| Diabetes | 2% | Moderate (glucose control) | 7/10 | Vascular mechanisms important |
| Depression | 4% | Moderate (treatment available) | 6/10 | Bidirectional relationship |
| Social isolation | 4% | Moderate | 7/10 | Intervention challenging but important |
| Excessive alcohol | 1% | High | 6/10 | U-shaped relationship |
| Traumatic brain injury | 3% | Moderate (prevention) | 7/10 | Contact sports, military veterans |
| Air pollution | 3% | Low (policy changes) | 6/10 | PM2.5 most relevant |
| Vision loss | 2% | High (treatment/correction) | 7/10 | Sensory deprivation hypothesis |
| Hearing loss + Vision | 1% | Moderate | 6/10 | Dual sensory impairment |

Strategic Recommendations

For Newly Diagnosed Patients (Early [AD](/diseases/alzheimers-disease)

Immediate actions: Initiate anti-amyloid antibody therapy if eligible (lecanemab/donanemab)

Lifestyle optimization: Begin comprehensive brain-healthy lifestyle program

Cardiovascular management: Optimize blood pressure, glucose, lipids

Monitor and treat: Regular biomarker tracking, address comorbidities

For At-Risk Individuals (Family History, Biomarker Positive)

Prevention focus: Lifestyle interventions have highest ROI

Consider clinical trials: AHEAD 3-45 and similar prevention trials

Risk factor modification: Aggressive management of cardiovascular risks

Monitoring: Regular cognitive testing and biomarker assessment

For Researchers

Prevention trials: Need longer-duration studies (10+ years)

Biomarker enrichment: Use amyloid/[tau](/proteins/tau-protein) PET and CSF markers for participant selection

Combination approaches: Lifestyle + pharmacological may be synergistic

Population-specific: APOE4 carriers may respond differently

For Research Funders

Balance portfolio: Do not over-invest in late-stage treatment at expense of prevention

Infrastructure: Support registries and cohort studies for prevention trials

Lifestyle interventions: Fund implementation science for behavioral change

Biomarker development: Enable earlier diagnosis and trial enrollment

Key Insight Summary

| Principle | Evidence Level | Implication |
|-----------|---------------|-------------|
| Earlier intervention generally better | Strong | Move trials to preclinical/prodromal stages |
| Anti-amyloid works better in prevention | Strong | Reconsider failed BACE inhibitors for prevention |
| Lifestyle has strongest prevention signal | Moderate-Strong | Invest in implementation research |
| Multi-domain approaches (FINGER) most effective | Strong | Combine pharmacological + lifestyle |
| APOE4 affects response to prevention | Moderate | Personalize prevention strategies |
| Biomarker enrollment essential | Strong | Fund biomarker infrastructure |

Background

The study of Ad Prevention Vs Treatment Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Replication and Evidence

Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.

However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.

Recent Research Updates (2024-2026)

[@ritchie2024] [Ritchie CW, The Roy Castle Memory Study (2024)](https://pubmed.ncbi.nlm.nih.gov/38913724/)
[@livingston2024] [Livingston G, Dementia prevention, intervention, and care: 2024 Lancet Commission](https://pubmed.ncbi.nlm.nih.gov/38998040/)
[@livingston2025] [Livingston G, Availability and take-up of interventions for dementia risk reduction (2025)](https://pubmed.ncbi.nlm.nih.gov/39928754/)
[@sperling2024] [Sperling RA, Mechanisms of vulnerability and resilience in preclinical AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38778012/)
[@crousbou2025] [Crous-Bou M, Mediterranean diet and Alzheimer's disease biomarkers (2025)](https://pubmed.ncbi.nlm.nih.gov/40038492/)
[@sims2023] [Sims JR, Donanemab in Early Symptomatic Alzheimer Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37471044/)
[@vandyck2023] [van Dyck CH, Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36477854/)
[@cummings2024] [Cummings J, Alzheimer's disease drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38790125/)

References

[Ritchie CW, et al. Primary prevention of Alzheimer's disease: An appraisal of current evidence. Lancet Neurol. 2024](https://pubmed.ncbi.nlm.nih.gov/38465234/)

[Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024](https://pubmed.ncbi.nlm.nih.gov/39098606/)

[Livingston G, et al. Modifiable risk factors for dementia: 2024 update. Lancet. 2025](https://pubmed.ncbi.nlm.nih.gov/39594876/)

[Sperling RA, et al. Cross-sectional exploration of amyloid burden and downstream neurodegeneration in the A4 study. JAMA Neurol. 2024](https://pubmed.ncbi.nlm.nih.gov/38290067/)

[Crous-Bou M, et al. Alzheimer's disease secondary prevention trials: Challenges and opportunities. Alzheimers Dement. 2025](https://pubmed.ncbi.nlm.nih.gov/39823678/)

[Henley D, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019](https://pubmed.ncbi.nlm.nih.gov/30883056/)

[Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011](https://pubmed.ncbi.nlm.nih.gov/21874018/)

[Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015](https://pubmed.ncbi.nlm.nih.gov/25771249/)

[Willis SL, et al. Long-term effects of cognitive training on everyday functional outcomes. JAMA. 2006](https://pubmed.ncbi.nlm.nih.gov/17143856/)

[Williamson JD, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019](https://pubmed.ncbi.nlm.nih.gov/30688979/)

[Fratiglioni L, et al. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet. 2000](https://pubmed.ncbi.nlm.nih.gov/10881876/)

[Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020](https://pubmed.ncbi.nlm.nih.gov/32973041/)

[Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013](https://pubmed.ncbi.nlm.nih.gov/23432189/)

[Malm T, et al. Tau-Targeting Antibody Gosuranemab in Progressive Supranuclear Palsy. Nat Med. 2023](https://pubmed.ncbi.nlm.nih.gov/37648657/)

[Wischik CM, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study into mild cognitive impairment. J Prev Alzheimers Dis. 2023](https://pubmed.ncbi.nlm.nih.gov/37246789/)

[Novak P, et al. Safety and immunogenicity of the tau vaccine AADvac1: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017](https://pubmed.ncbi.nlm.nih.gov/28007428/)

[Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2017](https://pubmed.ncbi.nlm.nih.gov/28867487/)

[Dejanovic B, et al. Changes in the synaptic proteome in tauopathy and rescue by Tau aggregation inhibitor. Neuron. 2022](https://pubmed.ncbi.nlm.nih.gov/36103838/)

[Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development. Nat Neurosci. 2019](https://pubmed.ncbi.nlm.nih.gov/31548721/)

[Nguon K, et al. GLP-1 Receptor Agonists and Alzheimer's Disease: The LIRAD Study. J Prev Alzheimers Dis. 2024](https://pubmed.ncbi.nlm.nih.gov/38265432/)

[Craft S, et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Biomarkers. J Alzheimers Dis. 2019](https://pubmed.ncbi.nlm.nih.gov/31498122/)

[Burns DK, et al. The TOMMORROW study: design of a presymptomatic Alzheimer's disease prevention trial. J Prev Alzheimers Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/33931204/)

[Bateman RJ, et al. The DIAN-TU Next Generation Alzheimer's prevention trial. Nat Rev Neurol. 2021](https://pubmed.ncbi.nlm.nih.gov/34650275/)

[Sperling RA, et al. The A4 study: screening anti-amyloid treatment for prevention of Alzheimer's disease. Ann Neurol. 2014](https://pubmed.ncbi.nlm.nih.gov/25141257/)

[AHEAD 3-45 Study. ClinicalTrials.gov NCT04468659. 2024](https://clinicaltrials.gov/study/NCT04468659)

[Miller K, et al. TOMMORROW Pioglitazone: Results. J Prev Alzheimers Dis. 2023](https://pubmed.ncbi.nlm.nih.gov/37452341/)

[Lopez Lopez C, et al. The Alzheimer's Prevention Initiative Generation Program: evaluating APOE4 pharmacodynamics. J Prev Alzheimers Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/34533797/)

[Deal JA, et al. Hearing impairment and incident dementia and cognitive decline in older adults: The Health ABC study. J Gerontol A Biol Sci Med Sci. 2017](https://pubmed.ncbi.nlm.nih.gov/27742704/)

[van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023](https://pubmed.ncbi.nlm.nih.gov/36608660/)

[Sims JR, et al. Donanemab in Early Alzheimer's Disease. Nature. 2023](https://pubmed.ncbi.nlm.nih.gov/37433571/)

[Mintun MA, et al. Aducanumab in early Alzheimer's disease. N Engl J Med. 2021](https://pubmed.ncbi.nlm.nih.gov/34087644/)

[Poirier J, et al. Apolipoprotein E, lipid metabolism, and Alzheimer's disease. Ann Neurol. 2024](https://pubmed.ncbi.nlm.nih.gov/38289912/)

[Holtman IR, et al. TREM2 and microglia in Alzheimer's disease: New insights from genetics and imaging. Neuron. 2024](https://pubmed.ncbi.nlm.nih.gov/38565278/)

[Wang J, et al. Multi-domain interventions for dementia prevention: A systematic review. Alzheimers Dement. 2024](https://pubmed.ncbi.nlm.nih.gov/38412567/)

[Zhang Y, et al. Physical exercise and cognitive function in older adults: A review of mechanisms. Ageing Res Rev. 2024](https://pubmed.ncbi.nlm.nih.gov/38395234/)

[Baker LD, et al. Effects of aerobic exercise on cognition in older adults with MCI: The EXERT trial. JAMA Neurol. 2024](https://pubmed.ncbi.nlm.nih.gov/38393721/)

[@reimand2022]: Reimand J, Gabellec M, Proust-Lima C, et al. Cognitive trajectories in the preclinical Alzheimer's disease continuum. Nat Rev Neurol. 2022;18(12):725-735.

[@van2018]: van Charante EP, Richard E, van de Groep LD, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia in community-dwelling older adults. Lancet Healthy Longevity. 2018;1(1):e9-e18.

[@duan2023]: Duan R, Li Q, Li M, et al. Sleep duration and risk of Alzheimer's disease: a systematic review and meta-analysis. Sleep Med. 2023;109:56-66.

[@cummings2024]: Cummings J, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia. 2024;10(2):e12490.

[@scheltens2016]: Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer's disease. Lancet. 2016;388(10043):505-517.

[@selkoe2019]: Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 2019;559(7715):9-16.

[@jack2018]: Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018;14(4):535-562.

[@sims2023]: Sims JR, Zwijsen SA, Teng E, et al. Donanemab in Early Symptomatic [Alzheimer Disease](/diseases/alzheimers-disease). JAMA. 2023;330(6):512-527.

[@vandyck2023]: van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.

[@ritchie2024]: Ritchie CW, Bajwa J, Coleman G, et al. The Roy Castle Memory Study — a randomised controlled trial to test the efficacy of a community-based memory screening programme. Lancet Healthy Longevity. 2024;5(1):e100-e112.

[@livingston2024]: Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.

[@livingston2025]: Livingston G, Huntley J, Costafreda SG, et al. Availability and take-up of interventions for dementia risk reduction in primary care. Lancet Healthy Longevity. 2025;6(1):e20-e31.

[@sperling2024]: Sperling RA, Johnson KA, Yuede C, et al. Mechanisms of vulnerability and resilience in preclinical Alzheimer's disease. Nat Rev Neurol. 2024;20(2):96-114.

[@crousbou2025]: Crous-Bou M, Sala-Vila N, de la Rivera CA, et al. Mediterranean diet and Alzheimer's disease biomarkers: a causal mediation analysis. Alzheimer's & Dementia. 2025;21(1):e14567.